Pancreatic Cancer Research

ResearcherJikei University School of MedicineActive in the last 2 years

Tadashi Uwagawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2162-2653; OpenAlex author ID A5102799040. Sources: OpenAlex.

Their work

Papers
25 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2011: 3 papers · 2012: 1 paper · 2013: 5 papers · 2014: none · 2015: 2 papers · 2016: 3 papers · 2017: 2 papers · 2018: 3 papers · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: 4 papers

Papers 25

  1. Signal heterogeneity in apparent diffusion coefficient map of magnetic resonance imaging in resectable pancreatic cancer: a new prognostic factor for biologica… Co-author DOI 10.1016/j.suronc.2025.102270↗
  2. Impact of Preoperative Osteosarcopenia and Postoperative Administration of Pancrelipase on the Prognosis of Borderline Resectable and Unresectable Locally Adva… First author DOI 10.1177/00031348241272420↗
  3. Prognostic Impact of a Decrease in Serum Carbohydrate Antigen 19-9 Levels After Preoperative Therapy for 4 Months or More for Borderline Resectable Pancreatic … Co-author DOI 10.1177/00031348241278016↗
  4. Changes in Skeletal Muscle Volume During Preoperative Chemotherapy Affect the Outcome of Pancreatic Cancer. Co-author DOI 10.1177/00031348241278021↗
  5. Effect of Chemoradiotherapy on Locoregional Recurrence After Pancreatectomy for Pancreatic Cancer. Co-author DOI 10.21873/anticanres.17229↗
  6. Claudin 7 as a possible novel molecular target for the treatment of pancreatic cancer. Co-author DOI 10.1016/j.pan.2018.10.009↗
  7. Glycogen synthase kinase-3β activity plays a key role in the antitumor effect of nafamostat mesilate in pancreatic cancer cells. Co-author DOI 10.1002/ags3.12025↗
  8. Pomalidomide promotes chemosensitization of pancreatic cancer by inhibition of NF-κB. Co-author DOI 10.18632/oncotarget.24577↗
  9. Pomalidomide enhanced gemcitabine and nab-paclitaxel on pancreatic cancer both in vitro and in vivo. Co-author DOI 10.18632/oncotarget.24608↗
  10. Recombinant thrombomodulin suppresses tumor growth of pancreatic cancer by blocking thrombin-induced PAR1 and NF-κB activation. First author DOI 10.1016/j.surg.2016.12.008↗
  11. Preoperative Platelet-to-Albumin Ratio Predicts Prognosis of Patients with Pancreatic Ductal Adenocarcinoma After Pancreatic Resection. Co-author DOI 10.21873/anticanres.11378↗
  12. Dual inhibition of nuclear factor kappa-B and Mdm2 enhance the antitumor effect of radiation therapy for pancreatic cancer. Co-author DOI 10.1016/j.canlet.2015.10.034↗
  13. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer. First author DOI 10.1016/j.jss.2016.06.047↗
  14. A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2. Co-author DOI 10.1158/0008-5472.can-15-2841↗
  15. Effect of NF-κB inhibition on chemoresistance in biliary-pancreatic cancer. Co-author DOI 10.1007/s00595-015-1129-z↗
  16. Radical Resection of a Primarily Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy Using Gemcitabine, TS-1, and Nafamostat Mesilate; Report of a Ca… Co-author DOI 10.9738/intsurg-d-13-00193.1↗
  17. Nuclear factor κB activity correlates with the progression and prognosis of pancreatic cancer in a mouse model. First author DOI 10.1007/s00595-012-0279-5↗
  18. Combination chemotherapy of serine protease inhibitor nafamostat mesilate with oxaliplatin targeting NF-κB activation for pancreatic cancer. First author DOI 10.1016/j.canlet.2013.01.019↗
  19. Inhibition of nuclear factor kappa-B enhances the antitumor effect of combination treatment with tumor necrosis factor-alpha gene therapy and gemcitabine for p… Co-author DOI 10.1016/j.jamcollsurg.2012.09.016↗
  20. Phase II study of gemcitabine in combination with regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer. Co-author DOI 10.1097/coc.0b013e31823a53b2↗
  21. Erlotinib-induced thrombocytosis in patients with recurrence of pancreatic cancer after distal pancreatectomy. Co-author DOI 10.1097/mpa.0b013e31828cf976↗
  22. Prognostic factors of unresectable pancreatic cancer treated with nafamostat mesilate combined with gemcitabine chemotherapy. First author PMID 23155291↗
  23. Nafamostat mesilate can prevent adhesion, invasion and peritoneal dissemination of pancreatic cancer thorough nuclear factor kappa-B inhibition. Co-author DOI 10.1007/s00534-011-0390-9↗
  24. Combination treatment using adenovirus vector-mediated tumor necrosis factor-alpha gene transfer and a NF-κB inhibitor for pancreatic cancer in mice. Co-author DOI 10.1016/j.canlet.2011.02.036↗
  25. Combination paclitaxel and inhibitor of nuclear factor κB activation improves therapeutic outcome for model mice with peritoneal dissemination of pancreatic ca… Co-author DOI 10.1097/mpa.0b013e31820b9257↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Koichiro Haruki · 17 shared papers, 2011–2025 · strength 1.82
  2. Kenei Furukawa · 15 shared papers, 2011–2025 · strength 1.57
  3. Yoshihiro Shirai · 11 shared papers, 2016–2025 · strength 1.45
  4. Toru Ikegami · 5 shared papers, 2024–2025 · strength 1.19
  5. Masashi Tsunematsu · 5 shared papers, 2024–2025 · strength 1.19
  6. Michinori Matsumoto · 5 shared papers, 2024–2025 · strength 1.19
  7. Katsuhiko K. Yanaga · 20 shared papers, 2011–2019 · strength 1.11
  8. Shinji Onda · 4 shared papers, 2024–2025 · strength 0.95
  9. Takeshi Gocho · 6 shared papers, 2012–2025 · strength 0.81
  10. Hiroaki Shiba · 15 shared papers, 2011–2018 · strength 0.78
  11. Norimitsu Okui · 3 shared papers, 2019–2025 · strength 0.59
  12. Yuki Fujiwara · 12 shared papers, 2011–2018 · strength 0.52
  13. Nobuhiro Saito · 5 shared papers, 2016–2018 · strength 0.36
  14. Takashi Horiuchi · 5 shared papers, 2016–2018 · strength 0.36
  15. Kyohei Abe · 1 shared paper, 2025 · strength 0.25
  16. Mitsuru Yanagaki · 1 shared paper, 2025 · strength 0.25
  17. Ryoga Hamura · 1 shared paper, 2025 · strength 0.25
  18. Shunta Ishizaki · 1 shared paper, 2025 · strength 0.25
  19. Yuta Yamada · 1 shared paper, 2024 · strength 0.21
  20. Sadamu Homma · 1 shared paper, 2019 · strength 0.10
  21. Hiroshi Sugano · 1 shared paper, 2018 · strength 0.08
  22. Taro Sakamoto · 1 shared paper, 2017 · strength 0.07
  23. Shouhui Yang · 1 shared paper, 2016 · strength 0.05
  24. Nader N Hanna · 1 shared paper, 2016 · strength 0.05
  25. Naotake Funamizu · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.